Erratum: Extended pre-exposure prophylaxis with lopinavir–ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial (The Lancet (2016) 387(10018) (566–573), (S0140673615009848), (10.1016/S0140-6736(15)00984-8));Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): A randomised controlled trial

The Lancet

Volumn 387, Issue 10018, 2016, Pages 566-573

  Nagot, Nicolas ^a,b,c   Kankasa, Chipepo ^d   Tumwine, James K ^e   Meda, Nicolas ^f   Hofmeyr, G Justus ^g,h   Vallo, Roselyne ^a,b   Mwiya, Mwiya ^d   Kwagala, Mary ^e   Traore, Hugues ^f   Sunday, Amwe ^g,h   Singata, Mandisa ^g,h   Siuluta, Chafye ^d   Some, Eric ^f   Rutagwera, David ^d   Neboua, Desire ^f   Ndeezi, Grace ^e   Jackson, Debra ^h   Maréchal, Valérie ^a,b   Neveu, Dorine ^a,b   Engebretsen, Ingunn M S ⁱ   Lombard, Carl ^j   Blanche, Stéphane ^k   Sommerfelt, Halvor ^i,l   Rekacewicz, Claire ^m   Tylleskär, Thorkild ⁱ   Van De Perre, Philippe ^a,b,c   more..

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF ZAMBIA   (Zambia)

^e MAKERERE UNIVERSITY   (Uganda)

^f UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

^g Cecilia Makiwane Hospital   (South Africa)

^h UNIVERSITY OF THE WESTERN CAPE   (South Africa)

ⁱ UNIVERSITY OF BERGEN   (Norway)

^j SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^k UNIVERSITÉ PARIS DESCARTES   (France)

^l NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^m French National Agency for Research on AIDS and Viral Hepatitis   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; RITONAVIR;

ADULT; AFRICA; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BREAST FEEDING; BURKINA FASO; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERCHOLESTEROLEMIA; HYPERNATREMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPONATREMIA; INFECTION RATE; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALARIA; MALNUTRITION; NEUTROPENIA; NEWBORN; OUTCOME ASSESSMENT; PHYSICIAN; PNEUMONIA; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; SOUTH AFRICA; THROMBOCYTOPENIA; UGANDA; ZAMBIA; AFRICA SOUTH OF THE SAHARA; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFANT; MULTICENTER STUDY; PREVENTION AND CONTROL; PROCEDURES; TRANSMISSION; VERTICAL TRANSMISSION;

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; BREAST FEEDING; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; LOPINAVIR; PRE-EXPOSURE PROPHYLAXIS; RITONAVIR;

EID: 84959571597     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(19)31044-X     Document Type: Erratum

References (30)

1. LM Mofenson Prevention of mother-to-child HIV transmission: can we meet the goal of global elimination of new pediatric infections? Curr Opin HIV AIDS 8 2013 443 446
2. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendation for a public health approach 2010 World Health Organization Geneva
3. CS Chasela, MG Hudgens, DJ Jamieson et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission N Engl J Med 362 2010 2271 2281
4. HM Coovadia, ER Brown, MG Fowler et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial Lancet 379 2012 221 228
5. MG Hudgens, TE Taha, SB Omer et al. Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission Clin Infect Dis 56 2013 131 139
6. DJ Jamieson, CS Chasela, MG Hudgens et al. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial Lancet 379 2012 2449 2458
7. C Kilewo, K Karlsson, A Massawe et al. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study J Acquir Immune Defic Syndr 48 2008 315 323
8. NI Kumwenda, DR Hoover, LM Mofenson et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission N Engl J Med 359 2008 119 129
9. A Bedri, B Gudetta, A Isehak for the SWEN Study group Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials Lancet 372 2008 300 313
10. Kesho Bora Study Group I de Vincenzi Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial Lancet Infect Dis 11 2011 171 180
11. RL Shapiro, MD Hughes, A Ogwu et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana N Engl J Med 362 2010 2282 2294
12. TK Thomas, R Masaba, CB Borkowf et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding - the Kisumu Breastfeeding Study, Kenya: a clinical trial PLoS Med 8 2011 e1001015
13. C Kilewo, K Karlsson, M Ngarina et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study J Acquir Immune Defic Syndr 52 2009 406 416
14. EG Chadwick, EV Capparelli, R Yogev et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results AIDS 22 2008 249 255
15. EG Chadwick, J Pinto, R Yogev et al. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy Pediatr Infect Dis J 28 2009 215 219
16. A Violari, MF Cotton, DM Gibb et al. Early antiretroviral therapy and mortality among HIV-infected infants N Engl J Med 359 2008 2233 2244
17. N Nagot, C Kankasa, N Meda et al. Lopinavir/ritonavir versus lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174 BMC Infect Dis 12 2012 246
18. V Avettand-Fenoel, ML Chaix, S Blanche et al. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01) J Med Virol 81 2009 217 223
19. F Rouet, DK Ekouevi, ML Chaix et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting J Clin Microbiol 43 6 2005 2709 2717
20. A Alioum, M Cortina-Borja, F Dabis et al. Estimating the efficacy of interventions to prevent mother-to-child transmission of human immunodeficiency virus in breastfeeding populations: comparing statistical methods Am J Epidemiol 158 2003 596 605
21. M Friedman Piecewise exponential models for survival data with covariates Ann Stat 10 1982 101 113
22. CA Peltier, GF Ndayisaba, P Lepage et al. Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda AIDS 23 2009 2415 2423
23. FDA Kaletra (lopinavir/ritonavir) oral solution label changes related to toxicity in preterm neonates http://www.natap.org/2011/newsUpdates/022811-02.htm 2011 (accessed April 10, 2014).
24. A Simon, J Warszawski, D Kariyawasam et al. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers JAMA 306 2011 70 78
25. JB Nachega, OA Uthman, J Anderson et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis AIDS 26 2012 2039 2052
26. WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection 2013 World Health Organization Geneva
27. P Van de Perre, T Tylleskar, JF Delfraissy, N Nagot How evidence based are public health policies for prevention of mother to child transmission of HIV? BMJ 346 2013 f3763
28. P Van de Perre, PA Rubbo, J Viljoen et al. HIV-1 reservoirs in breast milk and challenges to elimination of breast-feeding transmission of HIV-1 Sci Transl Med 4 2012 143sr3
29. L Tenthani, AD Haas, H Tweya et al. Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ('Option B+') in Malawi AIDS 28 2014 589 598
30. RL Shapiro, S Rossi, A Ogwu et al. Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana Antivir Ther 18 2013 585 590